Stability-indicating Reversed Phase-Ultra Performance Liquid Chromatography Method Development and Validation for Simultaneous Determination of Encorafenib and Binimetinib in Formulation
Abstract
A simple, accurate and precise stability indicating method was developed for the simultaneous estimation of the encorafenib (ECRB) and binimetinib (BMTB) in a dosage form by UPLC. Chromatographic elution was processed through a HSS C18 (100 x 2.1 mm, 1.8m) reverse phase column and the mobile phase composition of 0.01N KH2PO4 buffer (3.5 pH) and acetonitrile in the proportion of 55:45 was processed thru a column at a flow rate of 1.0 ml/min. Temperature of the column oven was kept at 30.0°C and the wavelength maximum of detection system was set to 294 nm. Retention times of ECRB and BMTB were found to be 0.767 min and 1.130 min respectively. Repeatability of the method was determined in the form of %RSD and findings were 0.3 and 0.6 for ECRB and BMTB respectively. The percentage recovery of the method was found to be 99.59% and 99.70% for ECRB and BMTB respectively. LOD, LOQ values obtained from regression equations of ECRB and BMTB were 0.51, 1.55mg/ml and 1.47, 4.44 mg/ml respectively. Regression equation of ECRB was y = 6684.x + 18102 and BMTB was y = 13118x + 2159. Two analytes were subjected for acid, peroxide, photolytic, alkali, neutral and thermal degradation studies and the results shown that the percentage of degradation was found between 0.76% and 6.88%. Retention times and total run time of two drugs were decreased and the developed method was simple and economical. So, the developed method can be adopted in industries as a regular quality control test for the quantification of ECRB and BMTB.
Keywords:
Encorafenib, Binimetinib, UPLC, Stability studies, Validation.DOI
https://doi.org/10.25004/IJPSDR.2020.120509References
Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Current Opinion in Oncology. 2018; 30 (2):125–133.
Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22): 3446–56.
FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations. U.S. Food and Drug Administration (FDA) (Press release). 27 June 2018. Archived from the original on 18 December 2019. Retrieved 28 June 2018.
Drug Trial Snapshot: Braftovi. U.S. Food and Drug Administration(FDA). 16 July 2018. Archived from the original on 19 December 2019. Retrieved 18 December 2019.
Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, Piao Y, Liu J, Cheng W, Bi X, Gong P, Song Z, Meng S. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Letters. 2016;370 (2): 332–44.
Koelblinger P, Dornbierer J, Dummer R. A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncology. 2017;13 (20):1755–1766.
Wu PK, Park JI. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Seminars in Oncology. 2015;42 (6): 849–62.
Ascierto PA, Schadendorf D, Berking C. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. The Lancet. Oncology. 2013;14 (3): 249–56.
Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. Clin. Chim. Acta. 2017;470: 8–13.
Kafiya Suroor, Kudaravalli Sreedevi. RP - HPLC method development & validation for the simultaneous estimation of encorafenib and binimetinib in API & tablet dosage form. International Journal of Science and Research. 2019;8(10):184-190.
ICH: Q2 (R1), Validation of analytical procedures: text and methodology; 2005.
ICH: Q2B. Harmonized Tripartite Guideline, Validation of Analytical Procedure: Methodology, IFPMA, in: Proceedings of the International Conference on Harmonization, Geneva; 1996.
Ramesh Guguloth, Madhukar A, Kannappan N, Ravinder A, Method development and validation of new RP- HPLC method for the determination of sofosbuvir tablet, J. Pharma Res. 2016;5(7):161-163.
Charde M S, Welankiwar A S, Chakole R D. Development of validated RP-HPLC method for the simultaneous estimation of atenolol and chlorthalidone in combine tablet dosage form. International Journal of Advances in Pharmaceutics. 2014; 3 (1):1-11.
Estella Hermoso de Mendoza A, Imbuluzqueta I, et al. Development and validation of ultra-high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues. J Chromatogr B: Anal Technol Biomed Life Sci.. 2011;879:3490–6.
Madhavi S, Prameela Rani A. Simultaneous reverse phase ultra- performance liquid chromatography method development and validation for estimation of Grazoprevir and Elbasvir. Asian J Pharm ClinRes.. 2018;11:100.
Ngwa G. Forced degradation studies as an integral part of HPLC stability indicating method development. Drug Delivery Technol.. 2010;10:56-9.
Kishore kumar L Mule. Rapid analytical method for assay determination for prochlorperazineedisylate drug substances by Ultra performance liquid chromatography. Int J Curr Pharm Res. 2017;9:118-22.
Published

